1-4 of 4
Marek Demissie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Clinical Trials & Observations
Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, M.D., Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen A Tran, Chur-Woo You, Bulent Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet
Journal: Blood
Blood blood.2024027008.
https://doi.org/10.1182/blood.2024027008
Published: 2025
Includes: Supplemental data
Journal Articles

Fitusiran Population Pharmacokinetic and Pharmacodynamic Modeling Utilizing Phase 3 Clinical Trial Data to Confirm Doses Tested in Phase 3 Trials to Support an Antithrombin-Based Dose Regimen

Kumpal Madrasi, Pratik Bhagunde, Sajida Iqbal, Marja Puurunen, Marek Demissie, Shauna Andersson, Sreeraj Macha, Malidi Ahamadi
Journal: Blood
Blood (2023) 142 (Supplement 1): 2614.
https://doi.org/10.1182/blood-2023-189409
Published: 2023
Journal Articles

A Population Pharmacokinetic (PopPK) Model to Characterize Efanesoctocog Alfa (BIVV001) Factor VIII (FVIII) Activity Levels in Patients with Severe Hemophilia A

Pratik Bhagunde, Qiang Lu, Marek Demissie, Annemieke Willemze, Suresh Katragadda
Journal: Blood
Blood (2022) 140 (Supplement 1): 8449–8450.
https://doi.org/10.1182/blood-2022-167483
Published: 2022
Journal Articles

A Physiologically Based Pharmacokinetic (PBPK) Model for Adults to Characterize BIVV001 Activity, a New Class of Factor VIII (FVIII) with High Sustained Factor Activity

Binfeng Xia, Suresh Katragadda, Donato Teutonico, Sreeraj Macha, Marek Demissie, Craig Benson
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-138894
Published: 2020